← Leaderboards
George Sledge
Indiana Univ-Purdue Univ At Indianapolis
$0
Attributed
$0
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 1
By mechanism
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Mitchell Goldman$10,867,864
- Kenneth H. Fife$1,137,888
- Mark R. Kelley$16,203,613
- C. Conrad Johnston$0
- Patrick J Loehrer$17,498,162
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsAntisense Nucleic AcidClinical ResearchClinical Trial Phase IHuman SubjectHuman Therapy EvaluationIntravenous AdministrationNeoplasm /Cancer ChemotherapyNeoplasm /Cancer GeneticsOncogenes
Grant awards (7)
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2002 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2001 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2000 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2000 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2000 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2000 · RR
ISIS 2503, &ANTISENSE INHIBITOR OF H RAS TO PATIENTS W/ ADVANCED CAN$0
M01 · FY2000 · RR